Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: A meta-analysis and systematic review

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Liu, Zhenmin ^a   Chen, Yi ^a   Tao, Renchuan ^a   Xv, Jing ^a   Meng, Jianyuan ^a   Yong, Xiangzhi ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; END STAGE LIVER DISEASE; GRAFT FAILURE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETRANSPLANTATION; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADVERSE EFFECTS; COMPARATIVE STUDY; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; ISOLATION AND PURIFICATION; SURVIVAL RATE; VIROLOGY;

HEPATITIS C VIRUS;

CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; RECURRENCE; SURVIVAL RATE; TACROLIMUS;

EID: 84910686152     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107057     Document Type: Article

References (39)

1. Cooke GS, Lemoine M, Thursz M, Gore C, Swan T, et al. (2013) Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat 20: 600- 601.
2. Gane EJ (2008) The natural history of recurrent hepatitis C and what influences this. Liver Transpl 14 Suppl 2: S36-44.
3. Ciria R, Pleguezuelo M, Khorsandi SE, Davila D, Suddle A, et al. (2013) Strategies to reduce hepatitis C virus recurrence after liver transplantation. World J Hepatol 5: 237-250.
4. Agarwal K, Barnabas A (2013) Treatment of chronic hepatitis C virus infection after liver transplantation. Dig Liver Dis 45 Suppl 5: S349-354.
5. Gordon RD, Shaw BW, Jr., Iwatsuki S, Esquivel CO, Starzl TE (1986) Indications for liver transplantation in the cyclosporine era. Surg Clin North Am 66: 541-556.
6. Canafax DM, Ascher NL (1983) Cyclosporine immunosuppression. Clin Pharm 2: 515-524.
7. Zeevi A, Duquesnoy R, Eiras G, Rabinowich H, Todo S, et al. (1987) Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc 19: 40-44.
8. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K (2003) Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38: 1282-1288.
9. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, et al. (2005) Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 129: 1031-1041.
10. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, et al. (2006) Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 12: 51- 57.
11. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, et al. (2004) Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 313: 42-47.
12. Samonakis DN, Germani G, Burroughs AK (2012) Immunosuppression and HCV recurrence after liver transplantation. J Hepatol 56: 973-983.
13. Berenguer M, Royuela A, Zamora J (2007) Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 13: 21-29.
14. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, et al. (2000) HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 32: 673-684.
15. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, et al. (2001) A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 234: 384-393; discussion 393-384.
16. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, et al. (1998) Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 28: 823-830.
17. Levy G, Grazi GL, Sanjuan F, Wu Y, Muhlbacher F, et al. (2006) 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 12: 1464-1472.
18. Shenoy S, Hardinger KL, Crippin J, Korenblat K, Lisker-Melman M, et al. (2008) A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients. Liver Transpl 14: 173-180.
19. Ben-Ari Z, Mor E, Bar-Nathan N, Shaharabani E, Shapira Z, et al. (2003) Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation. Transplant Proc 35: 612-613.
20. Kim RD, Mizuno S, Sorensen JB, Schwartz JJ, Fujita S (2012) Impact of calcineurin inhibitors on hepatitis C recurrence after liver transplantation. Dig Dis Sci 57: 568-572.
21. Lai JC, Verna EC, Brown RS, Jr., O'Leary JG, Trotter JF, et al. (2011) Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 54: 418-424.
22. Berenguer M (2005) What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 42: 448-456.
23. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, et al. (2002) Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36: 202-210.
24. Berenguer M, Aguilera V, San Juan F, Benlloch S, Rubin A, et al. (2010) Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 90: 1204-1209.
25. Levy G, Villamil FG, Nevens F, Metselaar HJ, Clavien PA, et al. (2014) REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. Am J Transplant 14: 635-646.
26. Villamil F, Levy G, Grazi GL, Mies S, Samuel D, et al. (2006) Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. Transplantation Proceedings 38: 2964-2967.
27. Firpi RJ, Soldevila-Pico C, Morelli GG, Cabrera R, Levy C, et al. (2010) The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci 55: 196-203.
28. Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, et al. (2009) Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 88: 1214-1221.
29. Barbier L, Garcia S, Cros J, Borentain P, Botta-Fridlund D, et al. (2013) Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors. J Hepatol 59: 1223-1230.
30. Dumortier J, Guillaud O, Boillot O (2013) Conversion from twice daily tacrolimus to once daily tacrolimus in long-term stable liver transplant recipients: a single-center experience with 394 patients. Liver Transpl 19: 529-533.
31. Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, et al. (1998) Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 65: 1044-1046.
32. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, et al. (2008) Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 14: 512-525.
33. Sgourakis G, Radtke A, Fouzas I, Mylona S, Goumas K, et al. (2009) Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 22: 892-905.
34. Foxton Mr QA, Muiesan P, Heneqhan MA, Portmann B, Norris S, Heaton ND, (2006) The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant: 1922-1929.
35. Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135: 982-989.
36. Savovic J, Jones H, Altman D, Harris R, Juni P, et al. (2012) Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess 16: 1-82.
37. Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, et al. (2004) Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 10: 1258-1262.
38. wiesner RH (1998) A long-term comparison of tacrolimus versus cyclosporine in liver transplantation: A report of the United States. TRANSPLANTATION: 493-499.
39. Mueller AR, Platz KP, Blumhardt G, Bechstein WO, Steinmuller T, et al. (1995) The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506? Clinical Transplantation 9: 176-184.